drug

Razadyne

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Massachusetts General Hospital
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
NCT00566735Phase 3Completed

KOLs & investigators

1
John D Matthews, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Massachusetts General Hospital
company
trial
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
PHASE3
trial
indication
Major Depression
indication
Bipolar Disorder
indication
Depressive Disorder, Major
indication
Psychotic Disorders
indication
KOL
John D Matthews, MD
KOL score —
person